HCW Biologics Inc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 0.15
Dividend & YieldN/A$ (N/A)
Beta N/A
Market capitalization 77.12M
Operating cash flow -9.97M
ESG Scores unknown

Company description

HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. The company was incorporated in 2018 and is headquartered in Miramar, Florida.

Sector: Healthcare - Industry: Biotechnology

Financial data

Financial Statements

Cashflow Statement 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities 766.39k -628.65k 1.89M
Total Cashflows From Investing Activities -1.46M -186.68k -35.02M
Net Borrowings 563.59k 563.59k
Total Cash From Financing Activities 13.45M 11.72M 49.27M
Change To Operating Activities -662.22k -2.12M -2.8M
Issuance Of Stock 60.29k 9.9k 56.03M
Net Income -7.29M -5.8M -12.86M
Change In Cash 5.22M 1.1M 3.27M
Effect Of Exchange Rate
Total Cash From Operating Activities -6.77M -10.43M -10.98M
Depreciation 421.82k 572.87k 543.6k
Change To Account Receivables -2.5M -2.5M 2.37M
Other Cashflows From Financing Activities -6.76M -6.76M -6.76M
Change To Netincome 1.76k 21.88k -140.5k
Capital Expenditures -1.46M -186.68k -47.26k

Income Statement 2019-12-31 2020-12-31 2021-12-31
Research Development 5.28M 7.17M 8.07M
Income Before Tax -7.29M -5.8M -12.86M
Net Income -7.29M -5.8M -12.86M
Selling General Administrative 2.08M 2.75M 5.29M
Gross Profit 4.1M
Ebit -7.37M -5.82M -13.37M
Operating Income -7.37M -5.82M -13.37M
Interest Expense -61.95k -61.95k -61.95k
Income Tax Expense
Total Revenue 4.1M
Cost Of Revenue
Total Other Income ExpenseNet 72.35k 22.32k 505.37k
Net Income From Continuing Ops -7.29M -5.8M -12.86M
Net Income Applicable To Common Shares -7.78M -7.07M -12.86M

Balance Sheet Statement 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 1.07M 1M 2.32M
Total Stockholder Equity -9.68M -16.72M 51.19M
Other Current Liabilities 1.8M
Total Assets 10.07M 15.4M 53.51M
Common Stock 1.1k 480 3.58k
Other Current Assets 236.29k 654.53k 1.44M
Retained Earnings -9.68M -16.72M -30.64M
Treasury Stock
Cash 7.36M 8.46M 11.73M
Total Current Liabilities 1.07M 1M 2.32M
Other Stockholder Equity
Property, Plant, and Equipment 2M 1.62M 1.12M
Total Current Assets 8.03M 12.15M 40.48M
Net Tangible Assets -9.68M -16.72M 51.19M
Net Receivables 2.5M 133k
Accounts Payable 392.33k 155.34k 223.66k


Insider Transactions

Here are the insider transactions of stock shares related to HCW Biologics Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
BYAM REBECCAConversion of Exercise of derivative security at price 0.14 per share.D2022-11-02Chief Financial Officer33.75k
BYAM REBECCAPurchase at price 2.58 per share.D2022-09-14Chief Financial Officer15k
BYAM REBECCAPurchase at price 2.58 - 2.65 per share.D2022-09-13Chief Financial Officer30k
WONG HING CPurchase at price 2.67 - 2.70 per share.D2022-09-09Chief Executive Officer10k
WONG HING CPurchase at price 2.55 - 2.58 per share.D2022-09-07Chief Executive Officer10k
BYAM REBECCAPurchase at price 2.55 - 2.56 per share.D2022-08-31Chief Financial Officer17.2k
BYAM REBECCAPurchase at price 2.54 - 2.57 per share.D2022-08-29Chief Financial Officer20k
BYAM REBECCAPurchase at price 2.50 - 2.59 per share.D2022-08-25Chief Financial Officer90.3k
BYAM REBECCAPurchase at price 2.08 - 2.46 per share.D2022-06-14Chief Financial Officer66.45k
WINER GARY MPurchase at price 2.13 - 2.27 per share.D2022-06-10Director3.5k
WONG HING CPurchase at price 2.19 per share.D2022-06-10Chief Executive Officer1.52k
WONG HING CPurchase at price 2.25 - 2.31 per share.D2022-06-09Chief Executive Officer3k
WINER GARY MPurchase at price 2.10 - 2.13 per share.D2022-06-07Director2k
GREENE RICK SCOTTPurchase at price 2.09 per share.D2022-06-02Director4.8k
JIAO JIN-ANConversion of Exercise of derivative security at price 0.14 - 0.21 per share.D2022-05-31Officer14.57k
RHODE PETERConversion of Exercise of derivative security at price 0.14 - 0.21 per share.D2022-01-14Officer1.72k
JIAO JIN-ANPurchase at price 2.42 per share.D2021-12-06Officer10k
FLOWERS LEEConversion of Exercise of derivative security at price 0.14 per share.D2021-12-01Officer4.29k
BYAM REBECCAConversion of Exercise of derivative security at price 0.14 per share.D2021-11-23Chief Financial Officer27k
WONG HING CPurchase at price 3.93 per share.D2021-08-31Chief Executive Officer3.83k
WONG HING CPurchase at price 3.94 per share.D2021-08-31Chief Executive Officer5.83k
WONG HING CPurchase at price 3.77 - 3.93 per share.D2021-08-30Chief Executive Officer18.5k
WONG HING CPurchase at price 3.76 - 3.84 per share.D2021-08-27Chief Executive Officer14.5k
GREENE RICK SCOTTPurchase at price 4.10 per share.D2021-08-25Director3.61k
FLOWERS LEEPurchase at price 3.95 - 4.08 per share.D2021-08-23Officer13.46k
BYAM REBECCAPurchase at price 4.40 per share.D2021-08-19Chief Financial Officer10k
BYAM REBECCAPurchase at price 4.40 per share.D2021-08-19Chief Financial Officer10k
FLOWERS LEEPurchase at price 4.25 per share.D2021-08-19Officer10.53k
FLOWERS LEEPurchase at price 4.29 per share.D2021-08-19Officer10.53k
GARRETT SCOTT TPurchase at price 4.77 per share.I2021-07-22Director125k
WONG HING CPurchase at price 4.77 per share.D2021-07-22Chief Executive Officer627.5k
WONG HING CD2021-07-22Chief Executive Officer10.34M
RHODE PETERPurchase at price 4.77 per share.D2021-07-22Officer12.5k
MEDMIRA CAPITAL LTD.D2021-07-22Beneficial Owner of more than 10% of a Class of Security3.59M
BYAM REBECCAPurchase at price 4.77 per share.D2021-07-22Chief Financial Officer25k
FLOWERS LEEPurchase at price 4.77 per share.D2021-07-22Officer31.25k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to HCW Biologics Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on HCW Biologics Inc

Here is the result of two systematic investment strategies applied to HCW Biologics Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on HCW Biologics Inc

The following chart shows the equity curve of the two systematic investment strategies applied to HCW Biologics Inc:

HCW Biologics Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of -19.28% on the backtest period.

Performance at glance

Performance

-19.28 %

Latent gain

-48.3 $

Invested capital

250.47 $

Annualized return

-56.71 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on HCW Biologics Inc

This is the result of two momentum investment strategies applied to HCW Biologics Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on HCW Biologics Inc

The following chart shows all the entries opened by the momentum investment system on HCW Biologics Inc:

HCW Biologics Inc momentum entries
  • The first momentum investment strategy would give 10.69% of return on HCW Biologics Inc. That represents 53.5$ of latent gain with 500.27$ of employed capital.
  • The second momentum investment strategy would give 0% of return on HCW Biologics Inc. That represents 0.0$ of latent gain with 0.0$ of employed capital.
Performance at glance (1Q Momentum)

Performance

10.69 %

Latent gain

53.5 $

Invested capital

500.27 $

Annualized return

-0.0 %
Performance at glance (2Q Momentum)

Performance

0 %

Latent gain

0.0 $

Invested capital

0.0 $

Annualized return

-0.0 %

Momentum equity curve on HCW Biologics Inc

The following chart shows the equity curve of the two momentum strategies applied to HCW Biologics Inc:

HCW Biologics Inc momentum equity

Note: the dividends potentially given by HCW Biologics Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on HCW Biologics Inc

The following chart shows the employed capital evolution of the two momentum strategies on HCW Biologics Inc since the beginning:

HCW Biologics Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on HCW Biologics Inc

Buy the dip entry openings on HCW Biologics Inc

HCW Biologics Inc

The performance achieved by the robo-advisor on HCW Biologics Inc is 0%. That represents 0.0$ of latent gain with 0.0$ of employed capital. The following chart shows HCW Biologics Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of HCW Biologics Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

0 %

Latent gain

0.0 $

Invested capital

0.0 $

Annualized return

-0.0 %

Equity curve of the strategy applied to HCW Biologics Inc

The following chart shows the result of the investment strategy applied to HCW Biologics Inc:

HCW Biologics Inc

Note: the dividends potentially given by HCW Biologics Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on HCW Biologics Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on HCW Biologics Inc:

HCW Biologics Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on HCW Biologics Inc

In this section, I will compare the three previous investment strategies applied to HCW Biologics Inc.

Equity curve comparison on HCW Biologics Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

HCW Biologics Inc investment strategy comparison

Employed capital comparison on HCW Biologics Inc

HCW Biologics Inc investment comparison

Performance comparison on HCW Biologics Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment -19.28% -48.3$ 250.47$ -56.71%
Momentum 1 quarter 10.69% 53.5$ 500.27$ 106.9%
Momentum 2 quarters 0% 0.0$ 0.0$ -0.0%
Non-directional 0% 0.0$ 0.0$ -0.0%
Annualized return comparison

Automatic investment

-56.71 %

Momentum 1Q

-0.0 %

Momentum 2Q

-0.0 %

Non-directional

-0.0 %

Correlated stocks

Here are the most positively and negatively correlated stocks with HCW Biologics Inc:

Positive correlations

Most correlated stocks this year


Most correlated stocks last 3 months

Negative correlation

Most negatively correlated stocks this year


Most negatively correlated stocks last 3 months

Note: The algorithm computes the probability of correlation between HCW Biologics Inc and the other stocks. There may be false positives or some missing correlated stocks. If the price of HCW Biologics Inc does not vary for 36 weeks, the correlation calculation result will be wrong.


Company information

Company name HCW Biologics Inc
Country United States
City Miramar
Address 2929 North Commerce Parkway
Phone 954 842 2024
Website www.hcwbiologics.com
FullTime employees 44
Industry Biotechnology
Sector Healthcare
Exchange XNAS
Ticker HCWB
Market www.nasdaq.com

HCW Biologics Inc ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 0
Peer Environment Performance unknown
Environment Percentile unknown
Palm Oil unknown
Nuclear unknown
Fur Leather unknown
GMO unknown
Coal unknown
Pesticides unknown
Animal Testing unknown

Social scores

Social ESG Factors Scores
Social Score 0
Peer Social Performance unknown
Social Percentile unknown
Highest Controversy unknown
Peer Highest Controversy Performance unknown
Adult unknown
Gambling unknown
Alcoholic unknown
Tobacco unknown
Catholic unknown
Controversial Weapons unknown
Small Arms unknown
Military Contract unknown
Peer Count unknown

Related Controversy:


Governance scores

Governance ESG Factors Scores
Governance Score 0
Peer Governance Performance unknown
Governance Percentile unknown

ESG at glance
Total ESG Scores: unknown
Environment Score: 0
Social Score: 0
Governance Score: 0

ESG Performance: unknown

Peer Group: unknown

Peer Esg Score Performance: unknown

Rating Year: unknown

Rating Month: unknown

Max Age: unknown

Percentile: unknown